Cardiff Oncology Announces Permanent CEO and New CFO and COO Appointments
On April 9, 2026, Cardiff Oncology announced a significant restructuring of its executive leadership team to support the next phase of growth for its lead oncology asset, onvansertib. Mani Mohindru, Ph.D., who previously served as Interim CEO, has been permanently appointed as President and Chief Executive Officer, effective immediately. Additionally, the company appointed Josh Muntner as Chief Financial Officer, effective April 6, 2026, and Ajay Aggarwal, MD, MBA, as Chief Operating Officer, effective April 27, 2026. Dr. Mohindruβs compensation includes a base salary of $655,000 and significant stock option grants. Mr. Muntner, an industry veteran with 25 years of experience, received an inducement grant of 486,650 stock options. Dr. Aggarwal joins from Aclaris Therapeutics with a base salary of $490,000. These leadership changes are intended to strengthen Cardiff's clinical development and financial operations as the company advances its Phase 2 trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC).